232 related articles for article (PubMed ID: 34250422)
21. Somatic Copy Number Abnormalities and Mutations in PI3K/AKT/mTOR Pathway Have Prognostic Significance for Overall Survival in Platinum Treated Locally Advanced or Metastatic Urothelial Tumors.
Bellmunt J; Werner L; Leow JJ; Mullane SA; Fay AP; Riester M; Van Hummelen P; Taplin ME; Choueiri TK; Van Allen E; Rosenberg J
PLoS One; 2015; 10(6):e0124711. PubMed ID: 26039708
[TBL] [Abstract][Full Text] [Related]
22. Overall Survival Update for Patients with Metastatic Castration-resistant Prostate Cancer Treated with Capivasertib and Docetaxel in the Phase 2 ProCAID Clinical Trial.
Crabb SJ; Griffiths G; Dunkley D; Downs N; Ellis M; Radford M; Light M; Northey J; Whitehead A; Wilding S; Birtle AJ; Khoo V; Jones RJ
Eur Urol; 2022 Nov; 82(5):512-515. PubMed ID: 35688662
[TBL] [Abstract][Full Text] [Related]
23. Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy.
Hildebrandt MA; Yang H; Hung MC; Izzo JG; Huang M; Lin J; Ajani JA; Wu X
J Clin Oncol; 2009 Feb; 27(6):857-71. PubMed ID: 19164214
[TBL] [Abstract][Full Text] [Related]
24. Common Genomic Aberrations in Mouse and Human Breast Cancers with Concurrent P53 Deficiency and Activated PTEN-PI3K-AKT Pathway.
Martinez JD; Mo Q; Xu Y; Qin L; Li Y; Xu J
Int J Biol Sci; 2022; 18(1):229-241. PubMed ID: 34975329
[TBL] [Abstract][Full Text] [Related]
25. Independent prognostic impact of plasma NCOA2 alterations in metastatic castration-resistant prostate cancer.
Fettke H; Kwan EM; Bukczynska P; Steen JA; Docanto M; Ng N; Parente P; Mant A; Foroughi S; Pezaro C; Hauser C; Nguyen-Dumont T; Southey MC; Azad AA
Prostate; 2021 Sep; 81(13):992-1001. PubMed ID: 34254334
[TBL] [Abstract][Full Text] [Related]
26. The significance of PTEN and AKT aberrations in pediatric T-cell acute lymphoblastic leukemia.
Zuurbier L; Petricoin EF; Vuerhard MJ; Calvert V; Kooi C; Buijs-Gladdines JG; Smits WK; Sonneveld E; Veerman AJ; Kamps WA; Horstmann M; Pieters R; Meijerink JP
Haematologica; 2012 Sep; 97(9):1405-13. PubMed ID: 22491738
[TBL] [Abstract][Full Text] [Related]
27. Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss.
de Bono JS; De Giorgi U; Rodrigues DN; Massard C; Bracarda S; Font A; Arranz Arija JA; Shih KC; Radavoi GD; Xu N; Chan WY; Ma H; Gendreau S; Riisnaes R; Patel PH; Maslyar DJ; Jinga V
Clin Cancer Res; 2019 Feb; 25(3):928-936. PubMed ID: 30037818
[TBL] [Abstract][Full Text] [Related]
28. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012.
Hussain M; Daignault-Newton S; Twardowski PW; Albany C; Stein MN; Kunju LP; Siddiqui J; Wu YM; Robinson D; Lonigro RJ; Cao X; Tomlins SA; Mehra R; Cooney KA; Montgomery B; Antonarakis ES; Shevrin DH; Corn PG; Whang YE; Smith DC; Caram MV; Knudsen KE; Stadler WM; Feng FY; Chinnaiyan AM
J Clin Oncol; 2018 Apr; 36(10):991-999. PubMed ID: 29261439
[TBL] [Abstract][Full Text] [Related]
29. Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells.
Marty B; Maire V; Gravier E; Rigaill G; Vincent-Salomon A; Kappler M; Lebigot I; Djelti F; Tourdès A; Gestraud P; Hupé P; Barillot E; Cruzalegui F; Tucker GC; Stern MH; Thiery JP; Hickman JA; Dubois T
Breast Cancer Res; 2008; 10(6):R101. PubMed ID: 19055754
[TBL] [Abstract][Full Text] [Related]
30. Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancer.
Gupta S; Hovelson DH; Kemeny G; Halabi S; Foo WC; Anand M; Somarelli JA; Tomlins SA; Antonarakis ES; Luo J; Dittamore RV; George DJ; Rothwell C; Nanus DM; Armstrong AJ; Gregory SG
Genes Chromosomes Cancer; 2020 Apr; 59(4):225-239. PubMed ID: 31705765
[TBL] [Abstract][Full Text] [Related]
31. The genetic variants in the PTEN/PI3K/AKT pathway predict susceptibility and CE(A)F chemotherapy response to breast cancer and clinical outcomes.
Li X; Zhang R; Liu Z; Li S; Xu H
Oncotarget; 2017 Mar; 8(12):20252-20265. PubMed ID: 28423632
[TBL] [Abstract][Full Text] [Related]
32. Prognostic Impact of Total Plasma Cell-free DNA Concentration in Androgen Receptor Pathway Inhibitor-treated Metastatic Castration-resistant Prostate Cancer.
Fettke H; Kwan EM; Bukczynska P; Ng N; Nguyen-Dumont T; Southey MC; Davis ID; Mant A; Parente P; Pezaro C; Hauser C; Azad AA
Eur Urol Focus; 2021 Nov; 7(6):1287-1291. PubMed ID: 32739405
[TBL] [Abstract][Full Text] [Related]
33. PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients.
Punnoose EA; Ferraldeschi R; Szafer-Glusman E; Tucker EK; Mohan S; Flohr P; Riisnaes R; Miranda S; Figueiredo I; Rodrigues DN; Omlin A; Pezaro C; Zhu J; Amler L; Patel P; Yan Y; Bales N; Werner SL; Louw J; Pandita A; Marrinucci D; Attard G; de Bono J
Br J Cancer; 2015 Oct; 113(8):1225-33. PubMed ID: 26379078
[TBL] [Abstract][Full Text] [Related]
34. Features of the reversible sensitivity-resistance transition in PI3K/PTEN/AKT signalling network after HER2 inhibition.
Goltsov A; Faratian D; Langdon SP; Mullen P; Harrison DJ; Bown J
Cell Signal; 2012 Feb; 24(2):493-504. PubMed ID: 21996585
[TBL] [Abstract][Full Text] [Related]
35. MicroRNA-126 Targeting PIK3R2 Inhibits NSCLC A549 Cell Proliferation, Migration, and Invasion by Regulation of PTEN/PI3K/AKT Pathway.
Song L; Li D; Gu Y; Wen ZM; Jie J; Zhao D; Peng LP
Clin Lung Cancer; 2016 Sep; 17(5):e65-e75. PubMed ID: 27236384
[TBL] [Abstract][Full Text] [Related]
36. Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies.
Tural D; Serdengecti S; Demirelli F; Öztürk T; İlvan S; Turna H; Özgüroglu M; Büyükünal E
Br J Cancer; 2014 Apr; 110(8):1968-76. PubMed ID: 24595002
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of total plasma cell-free DNA level and androgen receptor amplification in castration-resistant prostate cancer.
Kubota Y; Hatakeyama S; Yoneyama T; Yoneyama MS; Hamano I; Konishi S; Okamoto T; Yamamoto H; Yoneyama T; Hashimoto Y; Ohyama C
World J Urol; 2021 Sep; 39(9):3265-3271. PubMed ID: 33675416
[TBL] [Abstract][Full Text] [Related]
38. Identification of
Pearson HB; Li J; Meniel VS; Fennell CM; Waring P; Montgomery KG; Rebello RJ; Macpherson AA; Koushyar S; Furic L; Cullinane C; Clarkson RW; Smalley MJ; Simpson KJ; Phesse TJ; Shepherd PR; Humbert PO; Sansom OJ; Phillips WA
Cancer Discov; 2018 Jun; 8(6):764-779. PubMed ID: 29581176
[TBL] [Abstract][Full Text] [Related]
39. Clinical significance of genetic variations in the PI3K/PTEN/AKT/mTOR pathway in Korean patients with colorectal cancer.
Kim JG; Chae YS; Sohn SK; Kang BW; Moon JH; Lee SJ; Jeon SW; Park JS; Park JY; Choi GS
Oncology; 2010; 79(3-4):278-82. PubMed ID: 21412012
[TBL] [Abstract][Full Text] [Related]
40. Mutation of genes of the PI3K/AKT pathway in breast cancer supports their potential importance as biomarker for breast cancer aggressiveness.
Tserga A; Chatziandreou I; Michalopoulos NV; Patsouris E; Saetta AA
Virchows Arch; 2016 Jul; 469(1):35-43. PubMed ID: 27059323
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
